IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.901
EU - Europa 6.861
AS - Asia 4.991
SA - Sud America 1.980
AF - Africa 143
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 9
Totale 23.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.728
SG - Singapore 2.177
BR - Brasile 1.769
IE - Irlanda 1.628
SE - Svezia 1.612
CN - Cina 1.444
IT - Italia 734
HK - Hong Kong 645
DE - Germania 529
PL - Polonia 507
UA - Ucraina 498
FI - Finlandia 294
GB - Regno Unito 278
FR - Francia 246
RU - Federazione Russa 243
VN - Vietnam 216
IN - India 119
AR - Argentina 85
CA - Canada 75
BE - Belgio 73
AT - Austria 59
MX - Messico 55
ZA - Sudafrica 52
BD - Bangladesh 44
IQ - Iraq 42
TR - Turchia 41
EC - Ecuador 37
ID - Indonesia 34
JP - Giappone 32
ES - Italia 30
UZ - Uzbekistan 30
MA - Marocco 26
NL - Olanda 26
VE - Venezuela 23
CO - Colombia 22
PK - Pakistan 22
CZ - Repubblica Ceca 16
KE - Kenya 16
TN - Tunisia 15
AE - Emirati Arabi Uniti 14
PY - Paraguay 13
DO - Repubblica Dominicana 12
LT - Lituania 12
AZ - Azerbaigian 11
IL - Israele 11
JO - Giordania 11
NP - Nepal 11
JM - Giamaica 10
KZ - Kazakistan 10
AL - Albania 9
DZ - Algeria 9
IR - Iran 9
KG - Kirghizistan 9
BO - Bolivia 8
EU - Europa 8
PE - Perù 8
UY - Uruguay 8
BG - Bulgaria 7
CH - Svizzera 7
CL - Cile 7
EG - Egitto 7
LV - Lettonia 7
OM - Oman 7
CI - Costa d'Avorio 6
HR - Croazia 6
RS - Serbia 6
SA - Arabia Saudita 6
SK - Slovacchia (Repubblica Slovacca) 6
AU - Australia 5
CR - Costa Rica 5
HN - Honduras 5
PS - Palestinian Territory 5
XK - ???statistics.table.value.countryCode.XK??? 5
GE - Georgia 4
HU - Ungheria 4
LB - Libano 4
MY - Malesia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TH - Thailandia 4
AM - Armenia 3
AO - Angola 3
BN - Brunei Darussalam 3
DK - Danimarca 3
GA - Gabon 3
GR - Grecia 3
LU - Lussemburgo 3
MN - Mongolia 3
NO - Norvegia 3
PA - Panama 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MK - Macedonia 2
ML - Mali 2
Totale 23.883
Salva come PNG Salva come JPEG
Città #
Dublin 1.622
Chandler 1.375
Dallas 1.068
Singapore 1.061
Ashburn 1.039
Jacksonville 1.010
Nyköping 847
Hong Kong 645
Beijing 626
Warsaw 493
New York 334
Ann Arbor 277
Princeton 272
Medford 259
Dearborn 250
Cambridge 240
Los Angeles 240
Des Moines 208
The Dalles 200
Messina 170
Boardman 167
São Paulo 138
Buffalo 134
Munich 93
Woodbridge 84
Jinan 83
Tianjin 79
Brussels 71
Lancaster 70
Moscow 69
Wilmington 61
Pune 58
Ho Chi Minh City 56
Redondo Beach 55
Rio de Janeiro 55
Shenyang 55
Belo Horizonte 53
San Mateo 53
Hanoi 49
Frankfurt am Main 48
Vienna 47
Dong Ket 46
Brooklyn 43
Nanjing 42
Hebei 34
Johannesburg 33
Zhengzhou 33
Brasília 32
Council Bluffs 32
Houston 32
Turku 30
Montreal 29
London 28
Tashkent 28
San Francisco 27
Seattle 27
Tokyo 27
Porto Alegre 26
Haikou 25
Helsinki 25
Jakarta 25
Stockholm 24
Hangzhou 23
Nuremberg 23
Santa Clara 23
Campinas 21
Nanchang 21
Atlanta 20
Changsha 20
Goiânia 20
Guangzhou 19
Leawood 19
Ningbo 19
Taizhou 19
Boston 18
Curitiba 18
Jiaxing 18
Mexico City 18
Quito 18
Düsseldorf 17
Guarulhos 17
Milan 17
Chennai 16
Hyderabad 16
Taiyuan 16
Washington 16
Baghdad 15
Chicago 15
Denver 15
Nairobi 15
Toronto 15
Fuzhou 14
Grammichele 14
Rome 14
Sorocaba 14
São Bernardo do Campo 14
Dhaka 13
Duque de Caxias 13
Fort Washington 13
Lanzhou 13
Totale 15.111
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 395
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 174
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 168
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 167
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 163
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 162
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 159
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 155
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 154
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 151
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 143
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 139
[Serum levels of copper and zinc in patients with lung cancer] 138
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 137
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 137
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 136
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 132
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 131
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 129
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 129
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 128
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 128
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 127
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 126
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 125
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 125
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 125
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 125
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 124
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 123
The treatment of peritoneal carcinomatosis in elderly patients. 123
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 122
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 122
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 122
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 122
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 121
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 121
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 120
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 120
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors 119
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 118
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 118
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 118
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 117
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 117
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 117
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 117
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 116
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 116
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 116
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 115
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 115
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 115
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 114
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 114
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 114
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 114
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 113
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 113
Breast. La terapia primaria: stato dell'arte 113
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 113
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 112
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 111
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries 111
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 110
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 110
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 110
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 110
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 109
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 109
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 109
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 109
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 108
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 108
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 107
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 107
NSCLC and HER2: between lights and shadows 107
Biological parameters in breast cancer. 106
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 105
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 105
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 105
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 105
The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC). 104
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 104
Unusual relapse of hepatocellular carcinoma 104
Peritoneal carcinomatosis of colorectal origin. 103
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 103
I Tumori del coloretto. La chemioterapia della fase avanzata. 102
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 102
Extended RAS mutation testing on wild-type KRAS exon 2 metastatic colorectal cancer. 102
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 101
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 101
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 101
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 101
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 100
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 100
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 99
Gemcitabine (GEM) and liposomal doxorubicin (PLD) in recurrent/metastatic breast carcinoma: A phase II study 97
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 97
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 96
Totale 12.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.480
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.137 0 0 0 0 0 223 115 159 77 238 193 132
2021/20221.776 19 244 30 45 58 16 106 65 15 320 265 593
2022/20235.031 390 493 216 420 382 514 80 329 1.989 19 141 58
2023/20241.304 103 186 70 108 71 498 66 56 5 46 11 84
2024/20255.083 66 47 92 316 259 168 106 1.120 1.345 293 418 853
2025/20265.038 753 925 1.077 859 1.254 170 0 0 0 0 0 0
Totale 24.186